---
title: "CUTIA-B: CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration"
description: "CUTIA-B announced that its CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration of China, becoming the world's first topical finasteri"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/246635037.md"
published_at: "2025-06-30T09:24:02.000Z"
---

# CUTIA-B: CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration

> CUTIA-B announced that its CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration of China, becoming the world's first topical finasteride for the treatment of androgenetic alopecia. The drug works by inhibiting the conversion of testosterone to dihydrotestosterone in the scalp, providing a more convenient method of administration and reducing systemic drug exposure. This approval is based on the results of a Phase III clinical trial conducted in China, which showed that CU-40102 is effective and well-tolerated. The product will enhance the group's presence in the field of dermatological treatments

According to the Zhitong Finance APP, CUTIA-B (02487) announced that the group's CU-40102 (topical finasteride spray) has received marketing approval from the National Medical Products Administration of China. The approved indication for CU-40102 is the treatment of androgenetic alopecia, making it the world's first and only approved topical finasteride for this condition, as well as the first and only approved topical finasteride in China.

Finasteride, as a specific type II 5α-reductase competitive inhibitor, inhibits the conversion of testosterone to dihydrotestosterone in the scalp, which can treat androgenetic alopecia. Unlike oral finasteride, the topical formulation of CU-40102 allows patients to apply the medication directly and precisely to the scalp surface, reducing systemic exposure compared to oral medication. The group believes that CU-40102 as a topical medication will be more easily accepted by patients, providing an alternative solution for those with androgenetic alopecia and becoming a new medication option for patients.

This marketing approval is primarily based on the results of a phase III confirmatory clinical trial completed in China for CU-40102. The results of this clinical trial showed that CU-40102 effectively treats androgenetic alopecia, and the subjects using CU-40102 had good local tolerance at the application site.

As the first product approved by the National Medical Products Administration in the field of hair diseases and care, and the second product approved following CU-10201 (topical 4% minocycline foam), CU-40102 will further strengthen the group's commercialization layout in the treatment and care of a wide range of skin diseases. Additionally, CU-40102 has submitted a new drug application to the Department of Health of the Hong Kong Special Administrative Region government in April 2024

### Related Stocks

- [02487.HK - CUTIA-B](https://longbridge.com/en/quote/02487.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 11:01 ETAdults with Intellectual and Developmental Disabilities Face Critical Mental Health Care Gaps, New Study Finds | A new study from Special Olympics Health reveals that adults with intellectual and developmental disabilities (IDD) are  | [Link](https://longbridge.com/en/news/276462423.md) |
| 12:57 ETWinter Storm May Knock Out Power; CPSC Warns of Deadly Carbon Monoxide and Fire Risks | As a winter storm approaches, the U.S. Consumer Product Safety Commission (CPSC) warns of the dangers of carbon monoxide | [Link](https://longbridge.com/en/news/276364746.md) |
| 09:40 ETIn HelloNation, Dental Expert Terrance O'Keefe of Penfield, NY, Breaks Down What a Toothache Could Mean | In a recent HelloNation article, Dental Expert Dr. Terrance O'Keefe discusses the various causes of toothaches, emphasiz | [Link](https://longbridge.com/en/news/276241973.md) |
| 13:45 ETInventHelp Inventor Develops New Grip Lock Safety Bar (TRO-1559) | An inventor from Mississauga, ON, Canada, has developed the GRIP LOCK SAFETY BAR, a patent-pending invention designed to | [Link](https://longbridge.com/en/news/276476081.md) |
| 13:15 ETInventHelp Inventor Develops Heat Therapy Device for Hands & Wrists (TPL-346) | An inventor from Dearborn Heights, Mich., has developed a heat therapy device called the HEAT THERAPY MITTEN to alleviat | [Link](https://longbridge.com/en/news/276473114.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.